A liquid chromatographic (LC) method was developed to assess the potency of products that contain dehydroepiandrosterone (DHEA), a precursor hormone synthesized from cholesterol by the human adrenal cortex and converted to potent androgens and/or estrogens in peripheral tissues. Forty-five commercial products (both single and multi-ingredient) were subjected to analysis by the proposed method. A Zorbax R x C 18 column with a mobile phase containing acetonitrile-0.025M phosphate buffer (60 + 40), pH 3.50, and UV detection at 292 nm was used for 87% of the products. An alternative mobile phase containing methanol-0.025M phosphate (75 + 25), pH 3.50, was used to isolate DHEA from more complex product mixtures. Assay values varied from 0 to 109.5% of the declared amount with an overall mean value of 91.1%. The recoveries based on fortified products ranged from 96.4 to 101.2%, and the intraday precision (RSD, n = 5) varied from 0.50 to 1.66%.
D
ehydroepiandrosterone (DHEA; Figure 1 ) and its conjugate ester DHEA sulfate (DHEAS) are precursor steriodal hormones synthesized by the human adrenal cortex. They are derived from cholesterol and converted to potent androgens and/or estrogens in peripheral tissues throughout the body. The circulating levels of DHEA and DHEAS follow a cyclical pattern during aging, with very high levels in the fetus that drop after birth and childhood, rise again before puberty, and reach their highest levels in young adulthood. They progressively decline to very low levels (20% of peak value) after age 70 (1) . This rise and fall is in contrast to other adrenal steroids (glucocorticoids and mineral corticoids) which maintain serum levels during aging.
DHEA was first isolated from human urine in 1934 (2) and the sulfate ester 10 years later (3) . The accepted names for the steroid are dehydroepiandrosterone (5-androsten-3-$-ol-17-one) and dehydroisoandrosterone. DHEA became available as a naturally occurring dietary supplement following passage of the Dietary Supplement and Health Education Act (DSHEA) of 1994. It is widely distributed through health food stores and mail order outlets to be used for the treatment of DHEA deficiency during the aging process.
Animal studies have demonstrated beneficial effects of DHEA in preventing or delaying the onset of obesity, diabetes, heart disease, and enhancing the immune system (1) . A clinical study involving 8 men and 8 women (50-65 years old) showed that DHEA given at a replacement dosage level of 100 mg daily for 1 year induced an anabolic growth factor, increased muscle strength and lean body mass, activated immune function, and enhanced quality of life or wellness (4) . However, there is concern regarding dietary supplements containing DHEA, and adverse events have been reported for both men and women who take such products (5) . Among the signs and symptoms observed were palpitation, chest pain, arrythmias, abnormal liver and thyroid function tests, generalized rash, fainting, and dysuria. Dosage levels of dietary supplements range from 5 to 100 mg DHEA/unit in tablet or capsule form, with 25 and 50 mg the most common. It is formulated as a single active ingredient or combined with other steroids (e.g., pregnenolone), vitamins, and numerous herbal extracts, including gingko, ginseng, kava kava, and yohimbine. DHEA is also available in liquid form as a colloidal suspension and oral spray for sublingual use.
Despite the abundance of DHEA-containing products available, there are no analytical methods to determine their quality and potency. Over the past 15 years, many of the published methods have focused on the analysis of body fluids and tissues. Serum and tissue have been analyzed for DHEAS using enzyme linked immunosorbent assay (ELISA; 6, 7) and by enzymatic procedures with bioluminescence (8) . Radio-immunoassay (RIA) techniques have also been applied to serum (9, 10) . Total DHEA levels in serum have been determined following hydrolysis of DHEAS, extraction and derivatization using gas liquid chromatography (GLC; 11), and GLC-MS (mass spectrometry; 12, 13). DHEA as the raw material has been assayed using coulometric titration (14, 15) . Liquid chromatography (LC) has been used as a preliminary isolation step for thin-layer chromatography of serum (16) and for separation of thiazoyl derivatives of DHEA and other steroids (17) . LC in conjunction with MS has been used to determine low levels of DHEA and DHEAS in serum and plasma (18, 19) .
The present study describes a reversed-phase LC method with UV detection for the assay of DHEA. The procedure was successfully applied to a large cross-section of commercial products containing various concentrations of DHEA. The performance of the proposed method was evaluated with respect to linearity, precision, accuracy, limits of detection and quantitation, and chromatographic characteristics of various brands of LC columns. (h) Commercial products.-Dietary supplement products containing DHEA were obtained from local health food outlets and mail order establishments. Many of the products declared DHEA in combination with various standardized quantities of herbal extracts. Therefore, additional products containing specific quantities of these herbal extracts were also obtained for comparison and included: Asiatic ginseng (Panax ginseng C.A. Meyer), gingko (Gingko biloba L.), yohimbe bark (Pausnystalia yohimbe K. Schumann), kava kava (Piper methysticum Forster), gotu kola (Centella asiatica L.), and garcinia fruit (Garcinia cambogia Desr.). This solution was stable in diluent A or B for at least 3 months when stored under ambient conditions.
Experimental

Apparatus
Standard Solutions
(c) Working standard solutions (related steroids).-Individual solutions containing pregnenolone (0.05 mg/mL), androstenedione (0.02 mg/mL), and 7-keto DHEA (0.02 mg/mL) were also prepared in the appropriate diluent for quantitative purposes.
(d) Working standard solutions (miscellaneous steroids and ingredients: retention study).-The remaining steroids, (f), were prepared at a concentration of 0.05 mg/mL in both diluents. Various water-soluble vitamins (indicated on product labels), melatonin, α-lipoic acid, t-ferulic acid, p-aminobenzoic acid, piperine, L-carnitine, indole-3-carbinol, and chromium picolinate were prepared at a concentration of 0.002-0.05 mg/mL in each diluent to provide an on-scale response for retention data.
Procedure
(a) Tablets.-A composite was prepared by grinding 20 tablets to fine powder in a glass mortar or by grinding with a vibration ball mill and then by a glass mortar. An accurately weighed portion of the composite equivalent to 1 tablet was transferred to 100 mL volumetric flask; 60 mL acetonitrile (or methanol) was added, and mixture was shaken mechanically for 20 min. The extract was diluted to volume using the scheme outlined in Table 1 based on dosage level, mixed well, and allowed to stand for 30 min. Except for the lowest dosage (5 mg/unit), a second dilution was made to final concentration of 0.05 mg DHEA/mL.
(b) Capsules.-A composite was prepared by grinding contents of 20 capsules in a glass mortar. An accurately weighed portion of the composite equivalent to content of 1 capsule was transferred to 100 mL volumetric flask and procedure for tablets was followed, beginning with "60 mL acetonitrile (or methanol) was added…".
(c) Sublingual spray.-Contents of the container were mixed well and 5 spray doses (25 mg DHEA) were combined and accurately weighed into 150 mL beaker; 60 mL diluent A was added and mixture was sonicated for 5 min. The extract was quantitatively transferred to 100 mL volumetric flask with diluent A and diluted to volume. A 10.0 mL aliquot of this solution was diluted to 50 mL with diluent A.
(d) Colloidal suspension.-The container was mixed well and 2 droppersful (25 mg DHEA) were transferred and accurately weighed into 100 mL volumetric flask containing 60 mL diluent A. The mixture was sonicated 5-10 s and diluted to volume with diluent A. A 10.0 mL aliquot was diluted to 50 mL with diluent A.
System Suitability
The chromatographic system was allowed to equilibrate with mobile phase A for at least 1 h before use. The integrator response for DHEA from 50.0 µL working standard solution, (b), was adjusted to 60-80% full-scale within retention time range of 5-6 min. The relative standard deviation (RSD) for 5 consecutive 50.0 µL injections of this solution based on peak height measurement was not more than 1.5%. The resolution, R, for a test mixture containing DHEA (0.05 mg/mL) and testosterone (0.03 mg/mL) prepared in diluent A was not less than 2.5 (20) . Determination A suitable volume of diluted product extract in 3 mL glass syringe was passed through a 13 mm, 0.45 µm nylon membrane, and 50.0 µL of filtrate was injected into the chromatograph. Quantitation was performed by direct comparison of peak height response for the product extract with that for the working standard solution, (b), using duplicate injections of each with bracketing injection sequence. The DHEA concentration in solid dosage forms was calculated as follows:
where R u and R s = average peak height response (mm) of sample and standard solutions, respectively; C = concentration of working standard solution (mg/mL); DF = dilution factor (mL); AUW = average unit weight (g); and W = portion weight (g). The liquid preparations were calculated in a similar manner on a dosage basis (per spray or dropperful) and on a weight basis (mg DHEA/g). 
Recovery Study
Selected product composites of solid dosage forms containing DHEA alone and in combination with other active ingredients were used to estimate the accuracy of the proposed method. Accurately weighed composite portions were fortified with weighed quantities of DHEA and compared to nonfortified portions. Fortification levels were approximately equivalent to that found in the portion taken for the assay (100% level). Both acetonitrile and methanol were used as initial extractant and mobile phases A and B.
In addition, simulated tablet and capsule formulations were prepared and assayed by the proposed procedure. A tablet mixture consisted of 25 mg DHEA, 150 mg microcrystalline cellulose, 225 mg dicalcium phosphate, 15 mg talc, 2.5 mg powdered vegetable stearin, and 2.0 mg colloidal silica. The capsule preparation consisted of 25 mg DHEA, 125 mg microcrystalline cellulose, 100 mg calcium carbonate, and 1.5 mg magnesium stearate.
Results and Discussion
The analytical results obtained using the proposed procedure for DHEA are shown in Tables 2 and 3 . The assay data represent 45 commercial products including tablets, capsules, and 2 liquid preparations. Nineteen of these products contained DHEA combined with other active ingredients of synthetic or botanical origin. The products were obtained from 34 different sources and claimed dosage levels for DHEA from 5 to 100 mg/unit. However, the data show that 53% of these products contained DHEA at 85-95% of the declared quantity with a mean of 91.1% within this range. Four products exceeded 100% of that declared and one (product C-9) was completely devoid of the active ingredient. The overall mean % declared for all products (excluding C-9) was 93.1.
DHEA was readily isolated and determined in 39 (87%) of the products using mobile phase A containing acetonitrile and phosphate buffer. An alternate mobile phase (B) of similar solvent strength containing methanol as the organic component was used to resolve DHEA from other active ingredients or herbal constituents in the remaining products. The retention time for DHEA was about 1 min longer using mobile phase B (6.5 versus 5.5 min). A liquid chromatogram of a 4-component reference standard mixture containing testosterone, DHEA, androsterone, and pregnenolone is shown in Figure 2 . Figure 3 shows typical chromatograms of a DHEA working standard solution and a single active ingredient tablet extract.
During development of the procedure, various conditions were optimized to include initial extraction media, extraction time and technique, mobile phase composition and pH, and UV detection wavelength. In the extraction study, representative products comprised both single and multi-ingredient tablets and capsules and a controlled-release tablet formulation. Composite portions equivalent to 1 tablet or capsule were taken for the assay versus a specific quantity of DHEA (e.g., 25 mg) to minimize the amount of excipient material initially extracted, particularly from lower dosage products and herbal-based preparations. The use of pure organic solvent (acetonitrile or methanol) as the primary extractant provided clear extracts, as compared with aqueous-organic mixtures or mobile phase which yielded turbid solutions or emulsions. Similar extraction efficiencies for DHEA were observed with either solvent. However, with DHEA-botanical formulations, acetonitrile solubilized less extraneous material than methanol, as shown by the comparative amount of residue obtained after evaporation of clear aliquots of the initial extract. A dilution protocol for the extracts based on product dosage level ( Table 1 ) is provided as a guide for the analyst in preparing the final sample solvent mixture having an aqueous-to-organic ratio equivalent to that of either mobile phase. This was necessary because slight variations in analyte response were observed when the sample solvent mixture and mobile phase were dissimilar. With the exception of the lowest dosage level (5 mg), the initial extraction and dilution are prepared in acetonitrile or methanol. An extraction time of 20 min was determined to be optimal based on consistent assay values for single or multi-ingredient tablets and capsules. The use of mechanical shaking was preferable to sonication, which increased the amount of extraneous material in the extract. A 0.025M phosphate buffer and mobile phase, pH 3.5, provided a suitable chromatographic response for DHEA over a range of 0.01-0.05M and pH 2.5-5.0, with acetonitrile as organic component and detector wavelength of 290 nm (21) . The acidic mobile phase allowed many additional formulation ingredients to elute early from the column. Sodium formate, used as an acidic buffer, suppressed the response for DHEA more than phosphate buffer.
DHEA had a UV maximum at 292 nm and a molar absorptivity (ε) of 40.8 when mobile phase A was the solvent. Despite the relatively low absorbance, this optimized detection wavelength provided both adequate sensitivity and selectivity with minimal background noise. It was also useful for detection of several related steroids.
The intralaboratory precision of the proposed procedure was evaluated from replicate determinations (n = 5) performed on the same day for 16 products. The mean assay values and RSDs are shown in Table 3 . The RSD values ranged from 0.50 to 1.66%, with an overall mean of 1.14%.
The accuracy of the procedure was assessed by determining recovery of DHEA from fortified commercial products. Fourteen products were used in this evaluation and the results presented in Table 4 show a range of 94.8-101.2%, with a mean recovery of 98.8%. Simulated tablet and capsule preparations were also used to estimate the accuracy of the method using mobile phase A. The tablet preparation contained 25 mg DHEA and dicalcium phosphate, microcrystalline cellulose, talc, powdered vegetable stearin, and colloidal silica. The cap- sule composite consisted of 25 mg DHEA with microcrystalline cellulose, calcium carbonate, and magnesium stearate. The recovery values obtained were 99.2 and 98.8% for the tablet and capsule mixtures, respectively. The lower value obtained for the capsule preparation was associated with the presence of magnesium stearate, based on additional assays for DHEA combined with individual synthetic components.
Many of the multi-ingredient products were formulated with various herbal extracts, 4 of which required the use of mobile phase B because of interferences with the DHEA response (T-12, T-18, C-14, C-17). Representative products included Asiatic ginseng, gingko biloba, yohimbe bark, kava kava, gotu kola, and garcinia fruit extract. The quantities taken for the determination were equivalent to that declared in the multi-ingredient DHEA formulation. The extracts were chromatographed using mobile phase A. With the exception of kava kava extract, no interferences were observed near the DHEA response. Product T-18 containing 25 mg standardized kava kava extract was assayed for DHEA using mobile phase B. Higher levels of kava kava extract (>25 mg) in a formulation will introduce a resolution problem with DHEA be- cause of increased levels of unsaturated styryl lactones from this botanical, whereby DHEA cannot be quantified. Although gingko biloba extract did not exhibit interferences, product C-17 containing gingko biloba leaf powder required the use of the alternate mobile phase. The chromatographic profiles for gingko biloba and gotu kola extract allowed tentative identification of these constituents in products T-9 and C-11. One formulation (product T-12) containing yohimbe bark extract in combination with 9 other botanical extracts also required mobile phase B. Attempts to assay for DHEA in a complex mixture consisting of 48 components including vitamins, minerals, and herbal extracts were unsuccessful when the proposed methodology was used. A preliminary isolation step was necessary in which DHEA was partitioned into methylene chloride from a buffered Celite 545 adsorbent mixture containing the sample (22) . Figure 4 represents product extracts containing DHEA and other active ingredients chromatographed with mobile phases A and B. The procedure can also be used to assay related steroids alone or in combination with DHEA. These include pregnenolone, 4-androstene-3, 17-dione (androstenedione), and 5-androsten-3$-ol-7, 17-dione-3-acetate (7-keto DHEA). The latter steroid is also labeled as 3-acetyl-7-oxo-dehydroepiandrosterone with certain products. Table 5 is a compilation of analytical results obtained for products containing these 3 steroids. Products T-9, T-15, and C-14 also contained DHEA. Product C-14 was labeled as a "hormonal synergist" to contain 50 mg DHEA, 50 mg androstenedione, and 250 mg Tribulus terrestris L., an herbal extract containing the steroidal sapogenin, diosgenin. Mobile phase B was used to separate DHEA and androstenedione in this product.
The chromatograms for 7 single ingredient products exhibited extraneous peaks in addition to DHEA that may be steroidal impurities. These peaks, having retention times of about 5.2 and 8.1 min with mobile phase A, were also present in DHEA reference material having 97% purity but at lower response levels. Figure 5 shows chromatograms of the product T-1 tablet extracts (2 different lots) exhibiting these unidentified peaks and for product T-2 from a different manufacturer.
Retention data for DHEA and a number of related steroids are summarized in Table 6 with mobile phases A and B. Although not formulated together, androstenedione and 7-keto DHEA cannot be resolved by using either mobile phase. These 2 steroids and DHEA were separated by using a ternary mobile phase composition of methanol-acetonitrile-0.025M KH 2 PO 4 (39 + 29 + 32, v/v/v), pH 3.50, with LC column (C) shown in Table 7 . The observed retention times were androstenedione, 8.60 min; 7-keto DHEA, 9.26 min; and DHEA, 9.64 min under these LC conditions. Table 6 shows retention data for various compounds formulated with DHEA. The response for piperine (5.43 min, mobile phase A), a component of black pepper, present in products C-13 and C-16, interfered with DHEA and required the use of mobile phase B.
A brief study was performed to determine the chromatographic characteristics for different brands of octadecylsilane-type LC columns. Comparative data related to the retention time of DHEA and the resolution (R) between DHEA and testosterone are shown in Table 7 for 8 columns including the brand used to develop the assay procedure (column G). The data indicate that columns B, E, and H are not suitable for this analysis based on the requirements outlined under system suitability and in part to differences in the surface chemistry of the packing materials.
The limits of detection (LOD), quantitation (LOQ), and linearity of response for DHEA with both mobile phase systems are shown in Table 8 . The correlation coefficient (r) values were based on 8 data points covering a concentration range of 0.001-0.10 mg DHEA/mL. 
